NASDAQ · HOWL
Werewolf Therapeutics, Inc.
Healthcare · Biotechnology
$0.96▼ 2.15% ($0.02)at close
After hours$0.97▲ 0.53%7:30 PM ET
Market cap
$46.65M
P/E
-1.31
EPS (TTM)
-$0.71
Next earnings
Nov 3, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
1 more note
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 7.9%
USD · TTM ending Jun 30, 2026 · Price used $0.96 · Price Sep 25, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 52.48% over the last year. Free cash flow grew 50.54% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -121.78%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
8
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 3, 2026
Q4 FY26 · EPS est -$0.22 · Revenue est $18.31M
View
Institutional Sentiment
Werewolf Therapeutics, Inc. · HOWL
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.